Project Grant R21HL184279
Award Date 8/15/26
Completion Date 8/14/28
Dollars Obligated $236K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $787,297 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 4, 2026. The award funds research into vascular dysfunction and lung allograft health, specifically investigating the mechanisms of primary graft dysfunction (PGD)—an ischemia-reperfusion injury that occurs in approximately 35 percent of lung transplants. The research examines how inflammasome-mediated pyroptosis and endothelial...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $729,984 under the Cardiovascular Diseases Research program (CFDA 93.837) on July 22, 2026. The award funds development of a three-dimensional real-time cardiovascular magnetic resonance imaging (3D RT CMR) reconstruction framework for imaging patients with cardiac arrhythmias. The proposed unsupervised reconstruction method, called Generative Prior with Multi-Dynamic Modeling (GEMM), enables highly accelerated 3D RT...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1,574,578 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel targeted modified mRNA delivery strategies for donation after circulatory death (DCD) heart transplantation. The research addresses primary graft dysfunction (PGD), an ischemia-reperfusion injury occurring in approximately 35 percent of heart transplants and driven by hyper-inflammatory responses involving...
- The National Heart, Lung, and Blood Institute awarded Medluidics LLC $227,639 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a cardiopulmonary unit-on-a-chip for investigating right ventricular hypertrophy caused by pulmonary arterial hypertension and for developing targeted treatments. The recipient will develop a microfluidic device that models both the right ventricle and pulmonary artery separated by a collagen layer, enabling culture of...
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytes—specialized mural cells that maintain capillary stability—transition into smooth muscle-like cells under...
- The National Heart, Lung, and Blood Institute awarded Research Institute At Nationwide Children's Hospital $1,326,945 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a translatable molecular imaging paradigm for comprehensive assessment of peripheral artery disease (PAD). The recipient will characterize stages of peripheral atherosclerosis using dual-phase PET/CT imaging with fluorine-18 sodium fluoride (18F-NAF) to quantify both regional muscle...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $1.102 million in funding under the Cardiovascular Diseases Research program (CFDA 93.837) on July 1, 2026, for a Project Grant (R35HL182842) supporting research into the regulation of ubiquitin E3 ligases and innate immunity in acute respiratory distress syndrome (ARDS). The research investigates immunosuppressive F-box proteins that degrade key substrates essential for host innate immunity and cytoprotective...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $190,188 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for a project grant titled "Fatty Acid Metabolic Drivers of Right Ventricular Dysfunction in Heart Failure Associated Pulmonary Hypertension." The award supports career development and mentored research for Dr. Jonah Garry to establish a patient-oriented translational research program focused on...
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $249,000 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize genetic variants associated with doxorubicin-induced cardiotoxicity using induced pluripotent stem cell-derived cardiomyocytes. The award funds research to identify genetic determinants of doxorubicin-induced cardiotoxicity and enable precise risk stratification and cardioprotection. The principal investigator...
- The National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health awarded The Ohio State University $121,658 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how inflamed adipose tissue modulates vascular inflammation through adipocyte-derived extracellular vesicles. The funded research decodes the role of adipocyte-derived extracellular vesicle cargo in promoting cardiovascular disease risk in obese populations. The...